Form 4: IN8BIO Director, Jeremy R. Graff, Reports Stock Option Grant

Director Jeremy R. Graff reports acquisition of stock options in IN8BIO, INC.

Summary

• Jeremy R. Graff, a director of IN8BIO, INC., filed a Form 4 on May 12, 2025.
• The report details the acquisition of stock options to purchase 63,150 shares of common stock at an exercise price of $0.17.
• The options were granted on May 8, 2025, and vest in equal monthly installments starting June 8, 2025, with full vesting by the next annual meeting of stockholders, contingent on continued service.
• Following the transaction, Graff directly owns 63,150 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment from the director.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the director to increase company value.

Key Dates

Keywords

IN8BIO, Form 4, stock options, director, beneficial ownership, securities, INAB, Jeremy R. Graff